Communiqués Lipocine Inc.

Actions

LPCN

US53630X2036

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/08/2026			Varia. 5j.	Varia. 1 janv.
2,100 ^USD	-1,41%		-0,47%	-73,85%

04/08	Lipocine Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
03/08	Lipocine Inc. annonce la nomination de Michael J. Grissinger à son conseil d'administration, à compter du 3 août 2026	CI

Communiqués

04/08	Lipocine: Q2 Earnings Snapshot	AQ
03/08	Lipocine : Appoints Michael J. Grissinger to Board of Directors	PU
05/06	Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154	AQ
08/05	Lipocine : Announces Financial Results for the First Quarter Ended March 31, 2026	PU
07/05	Lipocine: Q1 Earnings Snapshot	AQ
15/04	Lipocine : LPCN 1154 – Oral Brexanolone for Postpartum Depression (PPD)	PU
10/03	Lipocine: Q4 Earnings Snapshot	AQ
12/01	Lipocine : Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)	PU
19/11	Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression	AQ
06/11	Lipocine: Q3 Earnings Snapshot	AQ
26/08/25	Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025	PR
05/08/25	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025	PR
05/08/25	Lipocine: Q2 Earnings Snapshot	AQ
09/07/25	Lipocine : LPCN 1154 for Depression R&D Event, July 9th 2025	PU
26/06/25	Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression	PR
09/06/25	Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada	PR
14/05/25	Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase	PR
08/05/25	Lipocine: Q1 Earnings Snapshot	AQ
08/05/25	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025	PR
06/05/25	Lipocine Announces License and Supply Agreement for TLANDO® in Brazil	PR
26/03/25	Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154	PR
13/03/25	Lipocine Announces Financial Results for the Full Year Ended December 31, 2024	PR
12/03/25	Lipocine Announces FDA Labeling Changes for Testosterone Products	PR
06/02/25	Lipocine Receives Updated Regulatory Guidance on LPCN 1154	PR
17/12/24	Lipocine : FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis Form 8 K	PU